Cort

Recent Posts

Ongoing due diligence to support business development for midsize pharma company

Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a...
Learn More

Commercial supply chain for US launch of a blood cancer drug

Challenge: Our client was a publicly-traded clinical-stage biopharmaceutical company using an epigenetic approach modulate gene expression in tumor and immune cells to treat cancer. Their lead...
Learn More

Due Diligence of Late Stage Gene Therapy Asset

Challenge: Our client, a global pharmaceutical company, was facing a short deadline to making an offer for a late stage gene therapy asset and was under considerable competitive deal pressure. This...
Learn More

Life Science Consulting Case Studies

Over the past decade, our life science consulting team has provided expert guidance and hands-on support to companies, investors and academic research centers. What makes us unique is the first-hand...
Learn More

Landscape Analysis of the Radiopharma Market

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...
Learn More

Assessing the BD landscape for in-licensing & acquisition deals in GI

Challenge: A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be...
Learn More

Due diligence of a biotech with a novel single chain antibody platform

Challenge: A European investor asked Alacrita to conduct a due diligence exercise on a company that had developed a novel single chain antibody platform with its lead product in ADC format ahead of a...
Learn More

Regulatory assessment of a generic anti-diabetic peptide drug

Challenge: A biotech client had developed a generic version of a major anti-diabetic peptide drug, and wanted a clearer understanding of the product's registrability, as well as support with defining...
Learn More

Assessment of TLR immunomodulators in oncology and HIV

Challenge: A European publicly-listed biotech was facing a Phase III milestone for its lead immunomodulator and had a next generation technology in IND-enabling studies. The company was operating in...
Learn More

Deal benchmarks & term sheet appraisal for an early-stage license deal

Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...
Learn More

Investor Due Diligence: Pharma Business Development Case Studies

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
Learn More

Virtual Stewardship of a Targeted Cancer Therapy to an IND Submission

An early-stage biotech company developing a targeted cancer therapy engaged Alacrita to provide expertise to help them navigate an upcoming IND submission. An Alacrita partner and medical oncologist...
Learn More